October 8, 2015
Novartis:Long-term efficacy of Gilenya
Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya (fingolimod).
Pharmaceuticals, Biotechnology and Life Sciences
Tag: III FREEDOMS